Staging for Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: Utility of Incorporating Biologic Factors

被引:5
作者
Yi, Min [1 ]
Lin, Heather [2 ]
Bedrosian, Isabelle [1 ]
Shen, Yu [2 ]
Hunt, Kelly K. [1 ]
Chavez-MacGregor, Mariana [3 ,4 ]
King, Tari A. [5 ,6 ]
Mittendorf, Elizabeth A. [5 ,6 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Breast Surg Oncol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Hlth Serv Res, Houston, TX 77030 USA
[5] Brigham & Womens Hosp, Dept Surg, Div Breast Surg, 75 Francis St, Boston, MA 02115 USA
[6] Dana Farber Brigham & Womens Canc Ctr, Breast Oncol Program, Boston, MA 02215 USA
关键词
SURVIVAL; VALIDATION; BURDEN;
D O I
10.1245/s10434-019-07983-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. The American Joint Committee on Cancer (AJCC) breast cancer pathological prognostic stage, which incorporates biologic factors, was developed using data from patients undergoing upfront surgery, and its application in patients receiving neoadjuvant chemotherapy (NAC) is unknown. We previously developed the Neo-Bioscore, incorporating clinical and pathological TNM categories with biologic factors, to improve the prognostic stratification of NAC patients. Objective. This study was undertaken to evaluate the use of available staging models incorporating biologic factors in NAC patients. Methods. Patients treated with NAC between 2005 and 2012 at MD Anderson (n = 2363) were staged using the Neo-Bioscore and the AJCC 8th edition: (1) clinical anatomic stage; (2) pathological anatomic stage; (3) clinical prognostic stage; and (4) pathological prognostic stage. Five-year disease-specific survival (DSS) and overall survival (OS) rates, along with Harrell's concordance index (C-index), were estimated. A National Cancer Database (NCDB) cohort (n = 12,887) treated with NAC between 2010 and 2013 was used for validation. Results. In the MD Anderson cohort, staging systems incorporating biologic factors better predicted DSS (bias-corrected C-index: pathological prognostic stage = 0.8026; Neo-Bioscore = 0.7483) and OS (bias-corrected C-index: pathological prognostic stage = 0.7780; Neo-Bioscore = 0.7260) than those using anatomic factors only. Similar results were seen in the NCDB cohort. In pairwise comparisons, the pathological prognostic stage was significantly better (p < 0.0001) than other staging systems in all comparisons except for OS in the NCDB cohort, where it was not significantly different than the Neo-Bioscore (p = 0.2). Conclusion. Biologic factors are important for determining prognosis in patients receiving NAC. These data indicate that the 8th edition AJCC pathological prognostic stage is applicable in these patients.
引用
收藏
页码:359 / 366
页数:8
相关论文
共 20 条
[1]   Incorporation of Treatment Response, Tumor Grade and Receptor Status Improves Staging Quality in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy [J].
Bergquist, John R. ;
Murphy, Brittany L. ;
Storlie, Curtis B. ;
Habermann, Elizabeth B. ;
Boughey, Judy C. .
ANNALS OF SURGICAL ONCOLOGY, 2017, 24 (12) :3510-3517
[2]   Tumor Biology Correlates With Rates of Breast-Conserving Surgery and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer Findings From the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial [J].
Boughey, Judy C. ;
McCall, Linda M. ;
Ballman, Karla V. ;
Mittendorf, Elizabeth A. ;
Ahrendt, Gretchen M. ;
Wilke, Lee G. ;
Taback, Bret ;
Leitch, A. Marilyn ;
Flippo-Morton, Teresa ;
Hunt, Kelly K. .
ANNALS OF SURGERY, 2014, 260 (04) :608-616
[3]   Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis [J].
Cortazar, Patricia ;
Zhang, Lijun ;
Untch, Michael ;
Mehta, Keyur ;
Costantino, Joseph P. ;
Wolmark, Norman ;
Bonnefoi, Herve ;
Cameron, David ;
Gianni, Luca ;
Valagussa, Pinuccia ;
Swain, Sandra M. ;
Prowell, Tatiana ;
Loibl, Sibylle ;
Wickerham, D. Lawrence ;
Bogaerts, Jan ;
Baselga, Jose ;
Perou, Charles ;
Blumenthal, Gideon ;
Blohmer, Jens ;
Mamounas, Eleftherios P. ;
Bergh, Jonas ;
Semiglazov, Vladimir ;
Justice, Robert ;
Eidtmann, Holger ;
Paik, Soonmyung ;
Piccart, Martine ;
Sridhara, Rajeshwari ;
Fasching, Peter A. ;
Slaets, Leen ;
Tang, Shenghui ;
Gerber, Bernd ;
Geyer, Charles E., Jr. ;
Pazdur, Richard ;
Ditsch, Nina ;
Rastogi, Priya ;
Eiermann, Wolfgang ;
von Minckwitz, Gunter .
LANCET, 2014, 384 (9938) :164-172
[4]  
COX DR, 1972, J R STAT SOC B, V34, P187
[5]  
Hammond MEH, 2010, ARCH PATHOL LAB MED, V134, P907, DOI [10.1200/JCO.2009.25.6529, 10.1043/1543-2165-134.7.e48, 10.5858/134.6.907, 10.1200/JOP.777003]
[6]   THE MEANING AND USE OF THE AREA UNDER A RECEIVER OPERATING CHARACTERISTIC (ROC) CURVE [J].
HANLEY, JA ;
MCNEIL, BJ .
RADIOLOGY, 1982, 143 (01) :29-36
[7]  
Harrell FE, 2015, SPRINGER SER STAT, DOI 10.1007/978-3-319-19425-7
[8]   EVALUATING THE YIELD OF MEDICAL TESTS [J].
HARRELL, FE ;
CALIFF, RM ;
PRYOR, DB ;
LEE, KL ;
ROSATI, RA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1982, 247 (18) :2543-2546
[9]  
Hortobagyi G N., 2017, AJCC Cancer Staging Manual, V8th
[10]   Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy [J].
Jeruss, Jacqueline S. ;
Mittendorf, Elizabeth A. ;
Tucker, Susan L. ;
Gonzalez-Angulo, Ana M. ;
Buchholz, Thomas A. ;
Sahin, Aysegul A. ;
Cormier, Janice N. ;
Buzdar, Aman U. ;
Hortobagyi, Gabriel N. ;
Hunt, Kelly K. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (02) :246-252